Iconovo
Market Cap
kr489.9m
Last Updated
2021/04/11 18:23 UTC
Data Sources
Company Financials +
Executive Summary
Iconovo AB (publ) develops and licenses inhalation devices in Sweden. More Details
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential with excellent balance sheet.
Share Price & News
How has Iconovo's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ICO is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ICO's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
-0.3%
ICO
3.7%
SE Medical Equipment
2.8%
SE Market
1 Year Return
25.0%
ICO
42.4%
SE Medical Equipment
58.8%
SE Market
Return vs Industry: ICO underperformed the Swedish Medical Equipment industry which returned 42.4% over the past year.
Return vs Market: ICO underperformed the Swedish Market which returned 58.8% over the past year.
Shareholder returns
| ICO | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.3% | 3.7% | 2.8% |
| 30 Day | 9.4% | 1.9% | 4.5% |
| 90 Day | 21.6% | 6.9% | 13.8% |
| 1 Year | 25.0%25.0% | 43.3%42.4% | 63.5%58.8% |
| 3 Year | 88.6%88.6% | 110.9%101.7% | 74.9%54.5% |
| 5 Year | n/a | 116.9%82.6% | 103.9%62.2% |
Long-Term Price Volatility Vs. Market
How volatile is Iconovo's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
When Will Iconovo AB (publ) (STO:ICO) Turn A Profit?1 month ago | Simply Wall St
Have Iconovo AB (publ) (STO:ICO) Insiders Been Selling Their Stock?2 months ago | Simply Wall St
A Look At Iconovo's (STO:ICO) Share Price ReturnsValuation
Is Iconovo undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ICO (SEK63) is trading below our estimate of fair value (SEK262.7)
Significantly Below Fair Value: ICO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ICO is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.
PE vs Market: ICO is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ICO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ICO is overvalued based on its PB Ratio (5.3x) compared to the SE Medical Equipment industry average (5.1x).
Future Growth
How is Iconovo forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
57.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: ICO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ICO's is expected to become profitable in the next 3 years.
Revenue vs Market: ICO's revenue (32.2% per year) is forecast to grow faster than the Swedish market (3.5% per year).
High Growth Revenue: ICO's revenue (32.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ICO's Return on Equity is forecast to be high in 3 years time (24.1%)
Past Performance
How has Iconovo performed over the past 5 years?
-86.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICO is currently unprofitable.
Growing Profit Margin: ICO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ICO is unprofitable, and losses have increased over the past 5 years at a rate of 86.2% per year.
Accelerating Growth: Unable to compare ICO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ICO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.5%).
Return on Equity
High ROE: ICO has a negative Return on Equity (-18.48%), as it is currently unprofitable.
Financial Health
How is Iconovo's financial position?
Financial Position Analysis
Short Term Liabilities: ICO's short term assets (SEK74.4M) exceed its short term liabilities (SEK8.3M).
Long Term Liabilities: ICO has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ICO is debt free.
Reducing Debt: ICO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ICO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ICO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is Iconovo current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ICO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ICO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Johan Waborg
1.25yrs
Tenure
Mr. Johan Wäborg serves as Chief Executive Officer at Iconovo AB (publ) since 2020.
Leadership Team
Experienced Management: ICO's management team is considered experienced (2.3 years average tenure).
Board Members
Experienced Board: ICO's board of directors are considered experienced (4.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ICO insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Iconovo AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Iconovo AB (publ)
- Ticker: ICO
- Exchange: OM
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr489.888m
- Shares outstanding: 7.78m
- Website: https://www.iconovo.se
Number of Employees
Location
- Iconovo AB (publ)
- Medicon Village
- Scheeletorget 1
- Lund
- Skåne County
- 223 81
- Sweden
Listings
Biography
Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a reservoir-based dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a unit dose disposable dr...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 18:23 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.